Study guide
5.1 Insurance Policies, Billing & Letters of Medical Necessity
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
5.1 Insurance Policies, Billing & Letters of Medical Necessity
Key Takeaways Explain This Topic AI
Prior authorization and medical-necessity review—often via lab benefit managers—gate coverage for genetic tests; know what payers typically require before ordering.
Genetic counselors routinely navigate CPT/ICD-10 concepts, coverage policies, and billing roles without serving as certified billers; inaccurate coding or unsupported indications drive denials.
Letters of medical necessity (LMNs) succeed when they state the clinical indication, cite guideline or policy support, and explain how the result will change management.
Advocacy includes clarifying benefits, appealing denials with clinical evidence, and documenting medical necessity—without guaranteeing payment or promising coverage.
Board vignettes often contrast the best next finance step (verify benefits, submit PA, write LMN, appeal) with premature test ordering or vague reassurance about insurance.
Last updated: August 2026
Why finance literacy is a scored Domain 5A skill
Domain 5 (professional practice, finance, legal, and ethics) contributes 39 scored items . Subdomain 5A (7 scored) focuses on insurance policies , billing and reimbursement compliance , and letters of medical necessity (LMNs) . On the CGC exam, finance stems are rarely about memorizing a fee schedule. They test whether you can get the right test covered for the right indication , document necessity, and advocate without overpromising.
Coverage barriers are clinical barriers: a delayed hereditary cancer panel, a denied prenatal diagnostic test, or an unpaid consult can change reproductive timing, surgical decisions, and cascade testing. Boards reward counselors who treat insurance navigation as part of competent care—not as “someone else’s job.”
Insurance policies genetic counselors must understand
Payers publish medical policies (coverage criteria) for genetic tests and counseling. Policies differ by plan type (commercial, Medicare, Medicaid, marketplace) and often lag guidelines. Core concepts:
- Concept What it means clinically Exam cue
- Covered benefit Service is in the plan design (may still need PA) “Is genetic counseling even a benefit?”
Medical necessity Meets payer criteria linking indication → test → management Policy checklists, NCCN/ACMG-style thresholds
Prior authorization (PA) Approval required before the lab runs (or before billing) Do not draw/send until PA status is clear when required
- Network / lab channel Preferred labs or LBM-directed vendors Sending out-of-network → higher denial risk
- Exclusions Experimental/investigational lists; DTC exclusions WGS for “curiosity” often denied
- Appeals Formal reconsideration with clinical evidence Peer-to-peer, LMN, guideline citations
- Prior authorization workflow
Verify benefits for counseling and the specific test (CPT/panel name, lab).
Confirm medical policy criteria (phenotype, family history thresholds, prior negative testing, age/sex rules).
Submit PA with clinical documentation (notes, pedigree summary, ICD-10, guideline references).
Track determination (approved, denied, pending more info) before irreversible steps when possible.
Appeal or pivot (alternate covered test, self-pay options, hardship programs—see 5.3).
Trap: ordering the “best” panel clinically while ignoring a plan’s requirement to use a contracted lab or a narrower covered panel first. Another trap: telling the client “insurance will cover it” before verification.
Lab benefit managers (LBMs)
Many commercial plans outsource genetic-test utilization review to lab benefit managers . LBMs apply proprietary or payer-adopted criteria, may require online portals, and often enforce preferred laboratories. Practically:
PA may be obtained by the clinic, the lab’s prior-auth team, or both—clarify roles early.
LBM criteria can be stricter than specialty guidelines; document why the client meets policy language, not only why genetics “makes sense.”
Peer-to-peer review with a medical director is a common appeal path when the first denial cites “not medically necessary.”
Genetic counselors add value by translating phenotype and pedigree into the exact criteria language LBMs use (e.g., “first-degree relative with epithelial ovarian cancer,” “tumor IHC suggesting Lynch,” “ultrasound anomaly + desire for diagnostic testing”).
Medical necessity criteria for genetic tests
Medical necessity is not the same as clinical usefulness in the abstract. Payers typically want:
A specific indication (diagnosis, suspected syndrome, established familial variant, guideline-based screening).
Evidence that the test is not redundant (prior negative appropriate testing considered).
A clear statement that results will alter management (surveillance, surgery, pregnancy decisions, medication, cascade testing plan).
Use of a validated methodology appropriate to the indication (e.g., del/dup analysis when indicated; RNA studies when policy allows).
Indication pattern Common necessity anchors Frequent denial reasons
Hereditary cancer Personal/family history meeting guideline thresholds; known familial PV History “not strong enough”; wrong panel breadth
Prenatal diagnostic Ultrasound/NIPT indication; maternal age alone may be insufficient under some policies Screening vs diagnostic confusion; timing
Pediatric diagnosis Phenotype-driven differential; prior workup “Too broad” exome without phenotype justification
Pharmacogenetic Drug–gene pair with actionable labeling/guidelines Population screening without indication
Predictive / asymptomatic Documented familial variant; counseling completed Testing without known family variant when policy requires it
Coding and billing concepts GCs encounter
You are not expected to be a professional coder, but Domain 5A expects fluency with concepts that cause denials:
CPT codes describe the service (genetic counseling time-based codes where used; molecular pathology codes for tests—often billed by the lab).
ICD-10 codes must support the indication (Z-codes for family history/genetic carrier status; phenotype codes for symptomatic testing). Mismatch between diagnosis codes and the ordered test is a classic denial trigger.
Who bills matters: facility vs professional fee; lab billing the molecular CPT; GC services billed under a supervising provider in some settings.
Documentation must support medical necessity and time/complexity when counseling is billed.
Compliance : do not upcode indications, invent family history, or order tests solely to generate revenue. Fraud/abuse awareness belongs with professional integrity (Domain 5D) but appears in billing stems as “most appropriate documentation.”
Practical billing pitfalls
Using a nonspecific ICD-10 when a more precise phenotype or family-history code exists and is required by policy.
Assuming Medicaid and Medicare follow the same commercial LBM rules.
Confusing coverage of counseling with coverage of the test —either can be approved while the other is denied.
- Missing that some plans cover only certain genes on a panel and will deny “extras.”
- Letters of medical necessity: essential elements
An LMN is a clinician-authored letter (often drafted or co-authored by the GC) that argues why a specific service meets medical necessity. High-yield structure:
Patient identifiers and requesting clinician (brief).
Clinical indication — phenotype, diagnoses, relevant family history, prior testing and results.
Test requested — exact assay/panel/lab; why this test vs narrower/broader alternatives.
Guideline / policy support — cite applicable society guidelines, FDA labels when relevant, and map to the payer’s own medical policy criteria language.
How the result changes management — surveillance, risk-reducing surgery, pregnancy options, treatment selection, cascade testing—be concrete.
Risk of not testing — delayed diagnosis, inappropriate screening, missed relatives, irreversible decisions without information.
Closing request — approve coverage / overturn denial; offer peer-to-peer.
- LMN element Weak version Strong version
- Indication “Family history of cancer” Specifying cancers, ages, relationships, pathology
Guideline support “Guidelines recommend testing” Naming the criterion met (e.g., epithelial ovarian cancer in the patient)
Management change “Results would be helpful” “Pathogenic BRCA1 → discuss risk-reducing salpingo-oophorectomy timing; negative → revise surveillance per residual risk”
- Test choice “Large panel” Why genes included relate to differential; why del/dup or RNA add-on is needed
- Appeals without overpromising
Advocacy language: “Based on your history and this plan’s criteria, we will submit authorization and appeal if denied. Coverage is never guaranteed until the payer issues a determination.” Overpromising (“Don’t worry—they always cover BRCA panels”) is an exam distractor and an ethics risk when the client makes irreversible decisions on that assurance.
Integrated scenarios
Scenario A — hereditary breast cancer: Client meets guideline criteria; commercial plan routes PA through an LBM preferring Lab X. Best next step: verify benefits/PA channel and submit with documentation—not draw for Lab Y “because it’s faster” without checking network rules.
Scenario B — denial: Exome denied as “experimental” despite a child with a clear neurodevelopmental phenotype and nondiagnostic microarray. Best response: LMN mapping phenotype to policy exceptions/guideline support and requesting peer-to-peer—not telling the family the denial means testing has no clinical value.
Scenario C — prenatal: Couple wants diagnostic testing after high-risk NIPT; plan requires PA. Best counseling includes timing honesty: PA delay may push gestational age—discuss parallel self-pay options and urgency without guaranteeing approval.
Common traps
Ordering before PA when authorization is required and delay is avoidable.
Writing LMNs that list genes but never explain management impact.
Confusing clinical guidelines with automatic insurance coverage.
Guaranteeing payment or coaching clients to misstate history to meet criteria.
Ignoring LBM/lab channel requirements and blaming “insurance” generically after a preventable denial.
Quick exam checklist
Benefits verified for counseling and the specific test?
Policy/LBM criteria mapped to this client’s history?
PA status known before irreversible lab steps when required?
LMN includes indication, guideline/policy support, and management change?
Advocacy framed without coverage guarantees?